Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

Novo Nordisk › Novo Nordisk's (NYSE: NVO) leading medications have been hot discussion topics for years. Many Americans might ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity ...

Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy ...

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Novo Nordisk (NVO) shares rose 6% premarket on Thursday after a real-world study showed its diabetes drug Ozempic ...

Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds ...

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...